Loading…
Genpharmasec (BSE 531592)₹1.12+1.82%Trading & Distributors
In the Jun 2026 quarter (consolidated), Genpharmasec reported sales of ₹49.63 Cr, up 312.6% from Jun 2025, and net profit of −₹0.16 Cr, down 113.2% year on year. For the year to Mar 2026, sales were ₹140 Cr and net profit ₹0.99 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.85 | 6.37 | 10.19 | 5.19 | 6.02 | 8.47 | 14.00 | 12.03 | 32.61 | 39.79 | 55.39 | 49.63 |
| Expenses | 7.88 | 6.38 | 10.20 | 5.01 | 5.89 | 7.77 | 15.02 | 11.09 | 33.09 | 41.08 | 53.42 | 48.72 |
| Operating Profit | −0.04 | 0.02 | −0.02 | 0.21 | 0.14 | 0.73 | −1.01 | 0.95 | −0.47 | −1.25 | 2.00 | 0.97 |
| OPM % | −0.4% | 0.2% | −0.1% | 3.8% | 2.2% | 8.5% | −7.1% | 7.8% | −1.4% | −3.1% | 3.6% | 1.9% |
| Other Income | 0.14 | 0.15 | 0.30 | 0.56 | 0.74 | 0.80 | 0.93 | 0.68 | 0.45 | 0.97 | 1.01 | 0.36 |
| Interest | 0.06 | 0.00 | 0.17 | 0.11 | 0.06 | 0.15 | 0.10 | 0.13 | 0.24 | 0.40 | 0.49 | 0.39 |
| Depreciation | 0.00 | 0.13 | 0.04 | 0.17 | 0.31 | 0.11 | 0.27 | 0.28 | 0.57 | 0.68 | 0.69 | 0.68 |
| Profit before tax | 0.04 | 0.02 | 0.10 | 0.50 | 0.50 | 1.26 | −0.42 | 1.23 | −0.78 | −1.33 | 1.84 | 0.25 |
| Tax % | 80.0% | −100.0% | 345.5% | 35.3% | −39.2% | 40.2% | −37.2% | 2.4% | 48.1% | −37.3% | 27.1% | 165.4% |
| Net Profit | 0.00 | 0.05 | −0.26 | 0.32 | 0.69 | 0.75 | −0.26 | 1.21 | −1.17 | −0.82 | 1.35 | −0.16 |
| EPS (Rs) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | −0.01 | 0.00 | 0.02 | 0.00 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| Sales | 25.98 | 29.96 | 33.97 | 140 | 177 |
| Expenses | 24.98 | 29.98 | 33.01 | 139 | 176 |
| Operating Profit | 0.00 | 0.00 | 0.00 | 1.01 | 1.25 |
| OPM % | 1.0% | 0.1% | 0.2% | 0.9% | 0.7% |
| Other Income | 0.00 | 0.99 | 2.99 | 2.99 | 2.79 |
| Interest | 0.00 | 0.00 | 0.00 | 1.01 | 1.52 |
| Depreciation | 0.00 | 0.00 | 1.01 | 2.01 | 2.62 |
| Profit before tax | 0.00 | 0.00 | 1.99 | 0.99 | −0.02 |
| Tax % | −300.0% | 168.1% | 35.1% | 42.0% | — |
| Net Profit | 0.99 | 0.00 | 0.99 | 0.99 | −0.80 |
| EPS (Rs) | 0.01 | 0.00 | 0.01 | 0.02 | 0.01 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 28.06 | 55.11 | 55.14 | 55.10 |
| Reserves | −11.99 | 9.00 | 9.98 | 10.99 |
| Borrowings | 2.99 | 3.99 | 4.99 | 34.97 |
| Other Liabilities | 1.00 | 3.02 | 8.96 | 37.17 |
| Total Liabilities | 20.06 | 71.12 | 80.07 | 138 |
| Fixed Assets | 0.00 | 0.99 | 7.97 | 40.83 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.99 | 18.93 | 18.92 | 1.99 |
| Other Assets | 19.07 | 51.20 | 53.18 | 95.41 |
| Inventories | 9.70 | 8.85 | 8.21 | 13.90 |
| Trade receivables | 5.70 | 9.09 | 13.58 | 29.24 |
| Cash & equivalents | 1.98 | 18.80 | 5.26 | 10.06 |
| Total Assets | 20.06 | 71.12 | 80.07 | 138 |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from operating activity | −2.99 | −2.99 | 2.99 | −17.92 |
| Cash from investing activity | 0.00 | −28.04 | −15.02 | 13.01 |
| Cash from financing activity | 3.01 | 47.99 | −1.01 | 4.01 |
| Net cash flow | 0.00 | 17.07 | −14.05 | 0.00 |
| Capex | 0.01 | 0.01 | 5.70 | 3.68 |
| Free cash flow | −3.01 | −2.99 | −3.01 | −21.01 |
| CFO / OP % | −1,277.1% | −7,275.1% | 3,824.9% | −1,357.1% |
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor days | 81 | 108 | 147 | 75 |
| Inventory days | 150 | 132 | 103 | 38 |
| Days payable | 22 | 37 | 106 | 91 |
| Cash conversion cycle | 211 | 207 | 147 | 26 |
| Working capital days | 199 | 213 | 133 | 61 |
| ROCE % | — | 2.0% | 3.0% | 3.0% |
For the Jun 2026 quarter, Genpharmasec reported sales of ₹49.63 Cr, up 312.6% year on year and net profit of −₹0.16 Cr, down 113.2% year on year. The operating margin was 1.9%.
Genpharmasec's sales for the year to Mar 2026 were ₹140 Cr; over the last twelve months they were ₹177 Cr.
Net profit for the year to Mar 2026 was ₹0.99 Cr, and −₹0.80 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.01.
Genpharmasec reported borrowings of ₹34.97 Cr at Mar 2026, against cash and equivalents of ₹10.06 Cr.
Cash from operations was −₹17.92 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹21.01 Cr.